Danske Bank’s Viking Therapeutics VKTX Stock Holding History

Danske Bank’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-400	Closed	-$14.1K	–	1573
2025 Q4	$14.1K	Buy	+400	New	+$14.2K	﹤0.01%	1277
2024 Q4	–	Sell	-1,000	Closed	-$63.3K	–	1661
2024 Q3	$63.3K	Buy	+1,000	New	+$58.7K	﹤0.01%	1140
2024 Q2	–	Sell	-19,150	Closed	-$1.57M	–	1257
2024 Q1	$1.57M	Buy	+19,150	New	+$852K	﹤0.01%	751

Other funds holding VKTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Danske Bank's VKTX Position: Q1 2026 in Review

Danske Bank sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 400 shares — an estimated $14.1K sold.

Danske Bank first reported a position in VKTX in Q1 2024 and held it in 3 quarters. The position peaked at $1.57M in Q1 2024. 413 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Danske Bank reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Danske Bank sold 400 Viking Therapeutics shares in Q1 2026, an estimated $14.1K.
Danske Bank first reported a position in Viking Therapeutics in Q1 2024 and held it in 3 quarters.
Danske Bank's Viking Therapeutics position peaked at $1.57M in Q1 2024.
413 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Danske Bank's 13F filing for Q1 2026, filed 12 May 2026.